University of Virginia

HAMILTON, ON and BOSTON, Oct. 16, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, announced the appointment of Jeremy Bender, Ph.D., M.B.A., Teresa Bitetti, M.B.A., and David Meek to its Board of Directors, effective today. "We are excited to welcome Jeremy, Teresa and David to Fusion's Board of Directors, each bringing an exceptional breadth of experience and track record of success in oncology drug development, business development and commercialization. Their experiences introducing innovative therapies to cancer patients as leaders of top-tier oncology companies will be invaluable as we advance our pipeline, particularly our lead program FPI-2265, which is on track to be the first actinium-based PSMA targeted alpha therapy (TAT) to market," said Fusion Chief Executive Officer John Valliant, Ph.D. "Fusion is undergoing an exciting evolution to a later stage radiopharmaceutical company and with these appointments we are transforming our Board to maximize the value generation of our strategy." Dr. Bender, Ms. Bitetti and Mr. Meek succeed Johan Christenson, Ph.D., Chau Khuong and Heather Preston, M.D., who will step down from Fusion's Board effective today. "I want to thank Johan, Chau and Heather for their significant contributions and unwavering support that enabled Fusion to become a vertically integrated radiopharmaceutical company with a deep clinical-stage pipeline and a proprietary radiopharmaceutical manufacturing facility," Dr. Valliant said. Dr. Jeremy Bender is currently Chief Executive Officer of Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on pediatric cancer. Previously, Dr. Bender served as Vice President of Corporate Development at Gilead Sciences, overseeing acquisitions, partnerships and investments. He also served as Chief Operating Officer at Tizona Therapeutics, Chief Business Officer at Sutro Biopharma, and Vice President of Corporate Development at Allos Therapeutics, and began his career at Boston Consulting Group in the life sciences practice. He currently sits on the Board of Mereo BioPharma as an Independent Board Member. Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado and an M.B.A. from the MIT Sloan School of Management. Ms. Teresa Bitetti currently serves as President of the Global Oncology Business Unit of Takeda. Previously, Ms. Bitetti held various roles of increasing responsibility at Bristol-Myers Squibb Company (BMS), including as Senior Vice President, Head of Worldwide Oncology Commercialization. At BMS, she also served as Senior Vice President and Head of the U.S. Oncology business, President and General Manager of BMS Canada, and Worldwide Head of the BMS Virology business. Before BMS, Ms. Bitetti also held various roles of increasing responsibility at Mobil Oil Corporation. Ms. Bitetti currently serves on the board of Osmol Therapeutics as an independent director. Ms. Bitetti holds a B.A. from Wellesley College and an M.B.A. from the Darden School of Business at the University of Virginia. Mr. David Meek most recently served as Chief Executive Officer and Member of the Board of Directors of Mirati Therapeutics. Prior to this role, he served as the President, CEO and Board Member of FerGene and CEO and Board Member of Ipsen. Mr. Meek was previously an Executive Vice President and President of Oncology at Baxalta Incorporated in the leadup to the acquisition by Shire and Chief Commercial Officer of Endocyte, and he held executive leadership roles at Novartis Pharmaceuticals Corporation and Novartis Oncology. Mr. Meek has served on the boards of Pharmaceutical Research & Manufacturers of America and European Federation of Pharmaceutical Industries & Associations. He currently serves on the Board of Directors of uniQure N.V. and previously served on the Board of Directors of Entasis Therapeutics (acquired by Innoviva). Mr. Meek holds a B.A. from the University of Cincinnati. About Fusion Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha emitting payloads to tumors. Fusion's clinical portfolio includes: FPI-2265 targeting prostate specific membrane antigen (PSMA) for metastatic castration resistant prostate cancer currently in a Phase 2 trial; FPI-1434 targeting insulin-like growth factor 1 receptor currently in a Phase 1 trial; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1), currently in a Phase 1 trial. In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Response Inhibitors (DDRis) and immuno-oncology agents. The Company recently received IND clearance for FPI-2068, the first novel TAT under the collaboration, which targets EGFR-cMET. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. To support Fusion's growing pipeline of TATs, the Company has signed strategic actinium supply agreements with TRIUMF, Niowave, Inc. and BWXT Medical. Contact: Amanda Cray Senior Director of Investor Relations & Corporate Communications (617) 967-0207 [email protected] SOURCE Fusion Pharmaceuticals

Seven Sites Join Network as Clinical Associate Members CHICAGO, Oct. 12, 2023 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) announced that seven medical centers have joined the PFF Care Center Network (CCN) as Clinical Associate members, a new membership option. Each of these Clinical Associates will collaborate with an existing Care Center Network site to help bring the resources of the PFF to even more people living with pulmonary fibrosis (PF) and interstitial lung disease (ILD). The Care Center Network includes 81 CCN sites and seven Clinical Associates in 39 states. Continue Reading (PRNewsfoto/The Pulmonary Fibrosis Foundation) "With the addition of seven Clinical Associate members, we are actively addressing the critical need to expand access for patients with PF and ILD to the resources available from the PFF as well as connecting more patients with providers committed to advancing the diagnosis and treatment of PF," said Dr. Sonye Danoff, PFF Senior Medical Advisor, PFF Care Center Network. "Our Clinical Associates will extend care to additional people living with these serious conditions and, in collaboration with CCN sites, they will provide patient education, clinical care and research opportunities including clinical trials." The newly designated Clinical Associate members of the PFF Care Center Network are: Avera Medical Group Pulmonary & Sleep Medicine (Sioux Falls, SD): Dr. Fady Jamous, Center Director Chest Medicine Associates Center for Interstitial Lung Disease (South Portland, ME): Dr. Meagan Moore, Center Director ChristianaCare (Newark, DE): Dr. Renee Dixon, Center Director Ochsner LSU Health Shreveport – Academic Medical Center(Shreveport, LA): Dr. Prangthip Charoenpong, Center Director StatCare Pulmonary (Knoxville, TN): Dr. Eric Weaver, Center Director St. Luke's University Health Network (Fountain Hill, PA): Dr. Douglas Corwin, Center Director University of New Mexico (Albuquerque, NM): Dr. Nour Ass'ad, Center Director Through the CCN, Care Centers and Clinical Associates collaborate to promote and provide quality care to those living with PF. Each Clinical Associate is paired with a current Care Center member so they may collaborate to expand and improve pulmonary fibrosis care. While Care Centers offer complete multi-disciplinary care on site, Clinical Associates may refer patients for procedures or services they are unable to offer. Clinical Associates actively participate in the CCN in working groups and committees, including the Nurse and Allied Health Network, which provides professional development and networking opportunities. More than 250,000 Americans are living with PF and ILD and over 50,000 new cases are diagnosed annually. There are over 200 types of ILD, which are characterized by varied amounts of inflammation, scarring, or both. This damages the ability of the lungs to absorb oxygen from the air. PF means scarring of the lung and can be seen in many types of ILD. The 88 sites now operating in the PFF Care Center Network are: Alabama University of Alabama at Birmingham (Birmingham) Arizona St. Joseph's Hospital (Phoenix) Banner University Medical Center (Phoenix ) University of Arizona (Tucson) California Cedars-Sinai Medical Center (Los Angeles) Center for Advanced Lung Disease at Keck Medicine of USC (Los Angeles) Loma Linda University Medical Center (Loma Linda) Stanford Health Center (Palo Alto) University of California at Davis Interstitial Lung Disease Program (Sacramento) University of California at Los Angeles (Los Angeles) University of California at San Diego (San, Diego) University of California at San Francisco (San Francisco) Colorado National Jewish Health (Denver) University of Colorado Anschutz Medical Campus (Aurora) Connecticut Yale School of Medicine (New Haven) Delaware **ChristianaCare Pulmonary Associates (Newark) NEW Florida Cleveland Clinic Florida (Weston) University of Florida (Gainesville) University of Miami (Miami) University of South Florida – Tampa General Hospital (Tampa) Georgia Emory University Hospital (Atlanta) Piedmont Healthcare (Atlanta) Illinois Loyola University Medical Center (Maywood) Northwestern Memorial Hospital (Chicago) Rush University Medical Center (Chicago) University of Chicago (Chicago) Indiana Indiana University (Bloomington) Iowa University of Iowa (Iowa City) Kansas The University of Kansas Hospital (Kansas City) Kentucky University of Kentucky Research Foundation (Lexington) University of Louisville School of Medicine (Louisville) Louisiana **Ochsner LSU Health Shreveport – Academic Medical Center (Shreveport) NEW Tulane University School of Medicine (New Orleans) Maine **Chest Medicine Associates Center for Interstitial Lung Disease (South Portland) NEW Maryland Johns Hopkins University (Baltimore) University of Maryland Medical Center (Baltimore) Massachusetts Beth Israel Deaconess Medical Center (Boston) Massachusetts General Hospital (Boston) St. Elizabeth's Medical Center (Boston) Michigan Corewell Health East (Royal Oak) Henry Ford Health System (Detroit) Spectrum Heath System (Grand Rapids) University of Michigan Health System (Ann Arbor) Minnesota University of Minnesota Medical Center (Minneapolis) Mayo Clinic (Rochester) Missouri St. Luke's Hospital (Chesterfield) Washington University School of Medicine (St. Louis) Nebraska Creighton University (Omaha) University of Nebraska Medical Center (Omaha) New Hampshire Dartmouth Health (Hanover, NH) New Mexico **University of New Mexico (Albuquerque) NEW New York Columbia University Medical Center (New York) New York University School of Medicine (New York) Stony Brook University Hospital (Stony Brook) University of Rochester Medical Center (Rochester) Weill-Cornell Medical Center (New York) North Carolina Duke University Medical Center (Durham) LeBauer Health Care at Cone Health (Greensboro) University of North Carolina Chapel Hill (Chapel Hill) Ohio Cleveland Clinic (Cleveland) The Ohio State University Wexner Medical Center (Columbus) University of Cincinnati Medical Center (Cincinnati) Oklahoma OU Health (Oklahoma City) Oregon The Oregon Clinic (Portland) Pennsylvania Penn State Milton S. Hershey Medical Center (Hershey) **St. Luke's University Health Network (Fountain Hill) NEW Temple Health (Philadelphia) Thomas Jefferson University Hospital (Philadelphia) University of Pennsylvania (Philadelphia) University of Pittsburgh (Pittsburgh) Rhode Island Rhode Island Hospital (Providence) South Carolina Medical University of South Carolina, (Charleston) South Dakota **Avera Medical Group Pulmonary & Sleep Medicine (Sioux Falls) NEW Tennessee **StatCare Pulmonary (Knoxville) NEW Vanderbilt University Medical Center (Nashville) Texas Baylor University Medical Center (Dallas) Houston Methodist Hospital (Houston) University of Texas Southwestern Medical Center (Dallas) University of Texas Health Science Center (Houston) The University of Texas Health Science Center (San Antonio) Utah University of Utah Health Care (Salt Lake City) Vermont The University of Vermont Medical Center (Burlington) Virginia Inova Fairfax Medical Campus (Falls Church) University of Virginia Health Systems (Charlottesville) VCU Health (Richmond) Washington University of Washington Medical Center (Seattle) Wisconsin Froedtert & the Medical College of Wisconsin Froedtert Hospital (Milwaukee) University of Wisconsin (Madison) **Clinical Associates About the Pulmonary Fibrosis Foundation The mission of the Pulmonary Fibrosis Foundation is to accelerate the development of new treatments and ultimately a cure for pulmonary fibrosis. Until this goal is achieved, the PFF is committed to advancing improved care of patients with PF and providing unequaled support and education resources for patients, caregivers, family members, and health care providers. The PFF has a four-star rating from Charity Navigator and is an accredited charity by the Better Business Bureau (BBB) Wise Giving Alliance. The Foundation has met all of the requirements of the National Health Council Standards of Excellence Certification Program® and has earned the Guidestar Platinum Seal of Transparency. For more information, visit pulmonaryfibrosis.org or call 844.TalkPFF (844.825.5733). Contact: Dorothy Coyle, 773-332-6201 SOURCE The Pulmonary Fibrosis Foundation

Hiatt's expertise in medicine, insurance, and medical benefits management will support development of healthcare software solutions that deliver super-clean orders™ PLYMOUTH, Mass., Oct. 11, 2023 /PRNewswire/ -- FrontRunnerHC, a technology provider that helps labs and healthcare organizations instantly access the information needed to maximize reimbursements and enhance their patients' experience, has announced that Mark Hiatt, MD, MBA, MS is its new chief medical officer and vice president of clinical applications. Continue Reading "Dr. Hiatt is a perfect addition to FrontRunnerHC & will accelerate our ability to deliver solutions at the next level." Tweet this Dr. Mark Hiatt, Chief Medical Officer and VP of Clinical Applications, FrontRunnerHC Hiatt, who has served as chief medical officer for a national medical benefits manager, a biotechnology research company, and an accreditation body, said that joining FrontRunnerHC was the natural next step in his career evolution. Hiatt noted, "I've been passionate about making an impact in healthcare all my life. Being part of the FrontRunnerHC team gives me a direct opportunity to influence the development of the tools necessary to move the industry forward." Roughly 14 billion clinical lab tests occur in the United States each year, informing about 70% of medical decisions. Countless individuals are impacted by these lab tests on a daily basis. But according to John (JD) Donnelly, founder and CEO of FrontRunnerHC, the impact—both clinical and financial—extends beyond patients to labs, physicians, hospitals, and commercial and government payers. The importance and complexity of lab testing demand that the industry achieves a 'super-clean order'™, one that not only includes accurate patient information but also ensures that the ordered test will be covered by insurance and the patient gets the care they need. "Our healthcare system is ever changing and growing in complexity," noted Hiatt. "I know firsthand the challenges faced by physicians, labs, hospitals, insurers, and most importantly patients when it comes to getting all the necessary clinical and financial info for the patient upfront to ensure the best outcomes possible." Hiatt added that FrontRunnerHC has led the way in innovation before and is now on the road to transforming healthcare by building an integrated ecosystem that fosters information transparency and dialog. "A seismic shift is happening to break down traditional silos within the healthcare continuum to fundamentally disrupt and improve healthcare," said Donnelly. "Dr. Hiatt is a perfect addition to our team. His first-hand experience, clinical expertise, and passion for the changes needed to transform healthcare will accelerate FrontRunnerHC's ability to deliver solutions at the next level." Hiatt's educational background includes a fellowship in cardiovascular imaging at Stanford, residency in radiology and master's degree in Health Evaluation Sciences at the University of Virginia, and MD and MBA degrees from Wake Forest University. He also earned two bachelor's degrees in economics and Italian, with two minors in chemistry and zoology. Beyond his positions as chief medical officer, his professional experience includes executive medical director for a multi-state health insurance plan, leader of a clinical department, board member for a blockchain company and regional health system, senior vice president of market access and strategy and vice president of medical affairs for precision medicine companies, founding CEO of a healthcare consulting firm, and cardiovascular radiologist. Among his many accomplishments, Hiatt chaired his local chapter of the American Red Cross, was appointed by the governor of his state to serve on its Medical Education Council and Digital Health Service Commission, and was the voice of The Medical Moment on radio stations in two states. The Utah Business Magazine honored Hiatt as a Healthcare Hero. About FrontRunnerHC () FrontRunnerHC's data automation platform helps labs and healthcare organizations maximize reimbursement while also enhancing their patients' experience with instant access to patient demographic, insurance, and financial information. FrontRunnerHC finds, verifies, and fixes patient information in real-time or batch, and at any point during the care journey, leveraging its access to the largest payer network in the industry. Defining the patient experience as the clinical journey + the financial journey™, FrontRunnerHC helps address the challenges that jeopardize both the organization's ability to get paid and their patients' experience. FrontRunnerHC has been recognized by Inc. magazine on its list of "America's fastest-growing private companies" for five years in a row. Contact: John (JD) Donnelly, FrontRunnerHC Phone: 508-746-5500 Email: [email protected] SOURCE FrontRunnerHC